文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉耐药结核的紧迫危机与有前景的前进方向

The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward.
PubMed 文献 · Lancet Infect Dis · 2026-02-16

耐药结核病进入危险新阶段,高负担地区已报告贝达喹啉等新药耐药,广泛耐药结核治疗结局差、死亡率高。虽然研发管线增强,但监管批准仍需数年,作者认为核心障碍是道德与组织层面,而非科学,并建议建立同情用药支持平台以公平获取研究性药物。

要点

  • 高负担地区已报告贝达喹啉耐药,广泛耐药结核治疗结局差、死亡率高。
  • 新药审批滞后使患者缺乏有效选择,作者认为障碍在道德与组织层面。
  • 建议建立全球同情用药支持平台,在正式批准前公平获取研究性药物。

核心结论

  • 应对复杂耐药结核的核心障碍并非科学问题,而是道德与组织层面的障碍。

主要发现

  • 在高负担地区已报告对贝达喹啉等新药的耐药。
  • 某些地区贝达喹啉基线耐药率相当高。
  • 广泛耐药结核的治疗结局仍然很差,死亡率高得不可接受。

临床怎么用

  • 可借鉴贝达喹啉和德拉马尼的批准前获取项目经验,建立同情用药支持平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-resistant tuberculosis is entering a new and dangerous phase. Bedaquiline and other newer drugs have transformed drug-resistant tuberculosis treatment, yet resistance to these agents is now being reported across high-burden settings. In some regions, baseline bedaquiline resistance is substantial, treatment outcomes for extensively drug-resistant tuberculosis remain poor and mortality is unacceptably high. At the same time, the tuberculosis drug pipeline is stronger than it has been in decades, with several promising investigational compounds advancing to late-stage trials. However, regulatory approval remains years away, leaving people with few or no effective treatment options to wait-and often die-while drugs with potential benefit remain inaccessible. Here, we argue that the central barrier to addressing complex drug-resistant tuberculosis is not scientific, but moral and organisational. Drawing on lessons from earlier pre-approval access programmes for bedaquiline and delamanid, we propose the establishment of compassionate-use support platforms (CUSPs): coordinated, global mechanisms to facilitate equitable access to investigational tuberculosis drugs before formal approval. Well designed CUSPs could balance urgency with safety, share responsibility across stakeholders, strengthen diagnostic and pharmacovigilance capacity, and ensure that people with the most difficult-to-treat tuberculosis are not excluded from scientific progress.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Howell P, Stillo J, Reuter A, et al. The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward. Lancet Infect Dis. 2026. PMID: 41713477. doi:10.1016/S1473-3099(26)00003-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。